Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H16N4O5 |
| Molecular Weight | 368.3434 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(=NC2=C1C=CC(=C2)C(=O)N(CCC(O)=O)C3=CC=CC=N3)C(O)=O
InChI
InChIKey=UAHPICIFAZXXBO-UHFFFAOYSA-N
InChI=1S/C18H16N4O5/c1-21-13-6-5-11(10-12(13)20-16(21)18(26)27)17(25)22(9-7-15(23)24)14-4-2-3-8-19-14/h2-6,8,10H,7,9H2,1H3,(H,23,24)(H,26,27)
| Molecular Formula | C18H16N4O5 |
| Molecular Weight | 368.3434 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:08:05 GMT 2025
by
admin
on
Wed Apr 02 08:08:05 GMT 2025
|
| Record UNII |
7Y2ZU9WRD9
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1015167-31-3
Created by
admin on Wed Apr 02 08:08:05 GMT 2025 , Edited by admin on Wed Apr 02 08:08:05 GMT 2025
|
PRIMARY | |||
|
156028097
Created by
admin on Wed Apr 02 08:08:05 GMT 2025 , Edited by admin on Wed Apr 02 08:08:05 GMT 2025
|
PRIMARY | |||
|
7Y2ZU9WRD9
Created by
admin on Wed Apr 02 08:08:05 GMT 2025 , Edited by admin on Wed Apr 02 08:08:05 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
URINE
|
||
|
PARENT -> METABOLITE |
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
FECAL
|
||
|
PARENT -> METABOLITE |
after i.v. infusion of 5 mg of 14C dabigatran in healthy volunteers
PLASMA
|
||
|
PARENT -> METABOLITE |
after i.v. infusion of 5 mg of 14C dabigatran in healthy volunteers
URINE
|
||
|
PARENT -> METABOLITE |
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
FECAL
|
